# Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein

> **NCT00048880** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** HeFi-1 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT00048880
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11-05
- **Primary completion:** 2008-07-02
- **Final completion:** 2008-07-02
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048880, "Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00048880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*